Li Wende selected for "double dragon plan"
Release time:
2020-08-14
Li Wende was selected into the "Shuanglong Plan"
News from our newspaper Recently, the CPC Jinhua Municipal Committee Talent Work Leading Group announced the list of leading talents for entrepreneurship and innovation in the "Shuanglong Plan" of Jinhua City in 2017 , and Dr. Li Wende, deputy general manager of Jianfeng Health Technology Company, was selected.
"Shuanglong Plan" is a special plan for the introduction of high-end talents for entrepreneurship and innovation formulated by Jinhua City in accordance with the national and provincial "Thousand Talents Plan" and combined with local conditions. It aims to deeply implement the talent priority development strategy and accelerate the introduction of high-level Talents serve the development strategy of "comprehensive well-off and the rise of central Zhejiang, in key leading industries and emerging industries such as electronic information, automobiles and new energy vehicles, biomedicine, new energy, and Internet technology, a group of scientific and technological innovation teams that have reached the international advanced level and a group of entrepreneurial innovation leaders with outstanding industry status are introduced at home and abroad. Talents, a group of reserve talents with great potential for professional and technological development.
According to the spirit of relevant documents, the talents of the "Ssangyong Program" must have senior professional and technical positions or doctorates, be no more than 55 years old, and have high scientific and technological innovation capabilities, and their research fields are in line with Jinhua City. The development direction of key industries, leading innovation results, and great potential for professional and technological development. For the selected talents, Jinhua municipal party Committee and municipal government will give individual awards of 40 yuan, 20 yuan and 60 yuan and 30 yuan respectively according to the comprehensive evaluation results. the scientific research project funding is mainly used for the purchase of scientific research equipment, project research and development, personnel training and introduction, etc.
Dr. Li Wende has served as the main technical executive and senior management personnel in many well-known biomedical health enterprises in China for many years. He has in-depth theoretical research and rich practical experience in scientific research and development and in the development and utilization of food, health food, natural products, and the feasibility development and production of food ingredients. He once presided over and participated in a national development project, developed a variety of health foods such as Angli brand Xinbang tablets, and owned four patents. During the period of 2006-2008 , he served as the director of the Technical Committee of the Plant Promotion Branch of the China Medical Insurance Chamber of Commerce. After joining Jianfeng Health Technology Company, Dr. Li Wende served as deputy general manager and chief scientist, mainly responsible for the research and development of health food and natural product products.
2017 4 , Jianfeng Health submitted the selection materials of Dr. Li Wende to the Wucheng District Committee Talent Office. After multi-level examination and interview reply, it was finally selected into the talent list of the "Shuanglong Plan. It is reported that Dr. Li Wende received priority funding. (Xu Feng)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page